- Home
- FUN vs RAPT Comparison
FUN vs RAPT Comparison
Compare FUN & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUN | RAPT |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1987 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FUN | RAPT |
|---|---|---|
| Price | $15.93 | $57.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | $27.31 | ★ $56.22 |
| AVG Volume (30 Days) | 2.6M | ★ 6.2M |
| Earning Date | 02-19-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,137,510,000.00 | N/A |
| Revenue This Year | $13.96 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.13 | N/A |
| 52 Week Low | $12.51 | $5.67 |
| 52 Week High | $48.80 | $57.86 |
Technical Indicators
Market Signals| Indicator | FUN | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 78.75 |
| Support Level | $16.93 | $57.61 |
| Resistance Level | $18.92 | $57.86 |
| Average True Range (ATR) | 1.10 | 0.13 |
| MACD | -0.26 | -0.72 |
| Stochastic Oscillator | 1.84 | 51.72 |
Price Performance
Historical ComparisonAbout FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.